<?xml version="1.0" encoding="UTF-8"?>
<p>Both AD and FTD have familial and sporadic forms of the diseases. Amyloid beta precursor protein (
 <italic>APP</italic>) [
 <xref rid="pone.0241552.ref006" ref-type="bibr">6</xref>], presenilin 1 (
 <italic>PSEN1</italic>) [
 <xref rid="pone.0241552.ref007" ref-type="bibr">7</xref>], and presenilin 2 (
 <italic>PSEN2</italic>) [
 <xref rid="pone.0241552.ref008" ref-type="bibr">8</xref>, 
 <xref rid="pone.0241552.ref009" ref-type="bibr">9</xref>] are AD familial risk genes explaining &lt; 0.5% of AD cases with age of onset typically between 30–50 years of age, while progranulin (
 <italic>GRN</italic>) [
 <xref rid="pone.0241552.ref010" ref-type="bibr">10</xref>] and microtubule-associated protein tau (
 <italic>MAPT</italic>) [
 <xref rid="pone.0241552.ref011" ref-type="bibr">11</xref>–
 <xref rid="pone.0241552.ref013" ref-type="bibr">13</xref>] are FTD familial risk genes [
 <xref rid="pone.0241552.ref002" ref-type="bibr">2</xref>]. Apolipoprotein E (
 <italic>APOE</italic>) was suggested to play a role in late onset Alzheimer’s disease (LOAD), the sporadic form of AD, long before GWAS era [
 <xref rid="pone.0241552.ref014" ref-type="bibr">14</xref>]. GWAS confirmed role of variants in 
 <italic>APOE</italic> but additionally identified clusterin (
 <italic>CLU</italic>), phosphatidylinositol binding clathrin assembly protein (
 <italic>PICALM</italic>) [
 <xref rid="pone.0241552.ref015" ref-type="bibr">15</xref>], bridging integrator 1 (
 <italic>BIN1</italic>) [
 <xref rid="pone.0241552.ref016" ref-type="bibr">16</xref>], CD2 associated protein (
 <italic>CD2AP</italic>) [
 <xref rid="pone.0241552.ref017" ref-type="bibr">17</xref>, 
 <xref rid="pone.0241552.ref018" ref-type="bibr">18</xref>], complement C3b/C4b receptor 1 (
 <italic>CR1</italic>) [
 <xref rid="pone.0241552.ref019" ref-type="bibr">19</xref>], ATP binding cassette subfamily A member 7 (
 <italic>ABCA7</italic>) [
 <xref rid="pone.0241552.ref020" ref-type="bibr">20</xref>], and CD33 molecule (
 <italic>CD33</italic>) [
 <xref rid="pone.0241552.ref017" ref-type="bibr">17</xref>, 
 <xref rid="pone.0241552.ref021" ref-type="bibr">21</xref>] to be associated with LOAD. Meta-analysis of 74,046 individuals by International Genomics of Alzheimer’s Project (I-GAP) revealed 19 GWAS significant AD loci including 11 novel loci [
 <xref rid="pone.0241552.ref021" ref-type="bibr">21</xref>]. These genes were implicated in cholesterol metabolism (
 <italic>APOE</italic>, 
 <italic>CLU</italic>, and 
 <italic>ABCA7</italic>), immune response (
 <italic>CR1</italic>, 
 <italic>CD33</italic>, 
 <italic>CLU</italic>, 
 <italic>ABCA7</italic>), and endocytosis (
 <italic>BIN1</italic>, 
 <italic>PICALM</italic>, 
 <italic>CD2AP</italic>) [
 <xref rid="pone.0241552.ref022" ref-type="bibr">22</xref>].
</p>
